Psilocybin Microdosing Side Effects: Anxiety, Headaches, Nausea, Sleep and What Research Shows

Psilocybin microdosing is often described as subtle, but subtle does not mean side-effect free. Research has reported anxiety, headaches, stomach discomfort, sleep disruption, fatigue and problems with focus, while the long-term safety picture remains incomplete.

Psilocybin microdosing can cause side effects. Reported effects include anxiety, headaches, nausea and other gastrointestinal discomfort, sleep problems, changes in appetite, fatigue or restlessness, and difficulty concentrating. Most side effects documented in microdosing research have been described as mild and temporary. That does not mean they occur in everyone, and it does not establish that repeated psilocybin use is safe over months or years. A major limitation of the research is that many microdosing studies have not systematically tracked adverse effects at all.

That distinction matters because online discussions often frame a microdose as too small to cause meaningful negative effects. The available evidence does not support that assumption.

What are the most common side effects of psilocybin microdosing?

Research has associated psychedelic microdosing with several categories of unwanted effects:

• Anxiety or increased nervousness
• Headache or migraine
• Nausea and stomach discomfort
• Reduced appetite
• Insomnia or disrupted sleep
• Fatigue or low energy
• Restlessness or overstimulation
• Difficulty concentrating
• Mental confusion or racing thoughts
• Changes in perception or bodily sensations
• Temporary increases in blood pressure

A 2025 systematic review examining 31 studies of LSD and psilocybin microdosing concluded that reported adverse effects were generally dose-dependent, mild and short-lived. Increased blood pressure, anxiety and cognitive impairment were among the more consistently identified concerns. A newer 2026 systematic review focused specifically on psilocybin mushroom and truffle microdosing found reports of gastrointestinal symptoms, appetite changes, anxiety, headaches, sleep problems, impaired focus, fatigue, restlessness and other forms of physical or psychological discomfort.

The important word is reported. Microdosing studies vary considerably in how they define a microdose, what substance participants actually take, how often they use it and whether researchers actively ask about side effects.

Can microdosing psilocybin cause anxiety?

Yes. Increased anxiety has appeared repeatedly in microdosing research. That can seem contradictory because reducing anxiety is also one of the reasons people report experimenting with psychedelics. But a substance being investigated for one effect does not mean it produces that effect consistently in every person. In a large survey of psychedelic microdosers, about 20% of respondents reported some type of negative psychological or physical effect. Psychological effects were the most commonly reported category and generally appeared during the period when the substance was active.

The 2026 psilocybin-specific review also identified increased anxiety, including social anxiety, among reported problems. Responses can vary with the individual, their mental state, expectations, other substances or medications, and the actual amount of psilocybin consumed. This is also why reported benefits of microdosing for anxiety should not be interpreted as evidence that microdosing reliably treats anxiety disorders.

Can microdosing cause headaches?

Headaches have been reported during microdosing, although research has not established exactly how frequently they occur or why some people experience them. The 2026 systematic review included headache among the physical symptoms reported by psilocybin microdosers. Broader reviews of psychedelic microdosing have also documented headaches in experimental and observational research. Headaches are not unique to microdosing. They have also been reported in research involving larger doses of psilocybin.

What remains unclear is whether repeated low-dose exposure changes headache frequency over time or whether particular individuals are more susceptible.

Can psilocybin microdosing cause nausea or stomach problems?

It can. Gastrointestinal symptoms are among the more commonly described physical complaints in the psilocybin microdosing literature. The 2026 review found gastrointestinal or appetite-related effects in several of the studies that actually reported side effects. These included nausea, stomach pain and decreased appetite. That does not establish how common these symptoms are among all people who microdose because more than half of the studies included in that review did not report side-effect data.

This missing data is one of the biggest problems when attempting to estimate the real risk.

Does microdosing affect sleep?

Sleep effects appear possible in both directions. Some research and user reports describe insomnia or difficulty sleeping. Other research has found changes in sleep duration after psychedelic microdosing. The current evidence is too inconsistent to say that psilocybin microdosing reliably improves or worsens sleep. The National Center for Complementary and Integrative Health specifically includes insomnia among reported negative effects of psilocybin microdosing. Broader research reviews have also documented sleep disturbance and insomnia in microdosing studies.

Someone feeling more stimulated or restless could experience a very different sleep response from someone who experiences fatigue. That variability is one reason claims that microdosing either improves sleep or inevitably causes insomnia should be treated cautiously.

Can a microdose make it harder to focus?

Possibly. Improved concentration and productivity are frequently cited reasons for microdosing, but controlled research has not consistently confirmed those benefits. Some studies have found no meaningful improvement in cognition, while others have detected small changes pointing toward impaired rather than improved cognitive performance. A double-blind, placebo-controlled psilocybin mushroom study involving 34 participants found noticeable acute subjective effects but no evidence of improved well-being, creativity or cognitive performance. Some measures instead showed small changes in the direction of cognitive impairment.

The 2026 systematic review also documented reports of impaired focus, mental confusion, memory problems and other cognitive complaints. This does not mean microdosing necessarily worsens concentration. It means the common claim that it reliably improves focus is stronger than the evidence currently supports.

Are microdosing side effects usually mild?

Most reported side effects in formal microdosing research have been mild and temporary. The 2025 systematic review reached that general conclusion after evaluating 31 studies. But there are several reasons not to turn that finding into “microdosing is proven safe.” First, many studies are short. They can tell researchers more about what happens over hours or weeks than what repeated exposure might do over years.

Second, adverse-event reporting is inconsistent. The August 2026 psilocybin review included 11 studies covering 3,262 adults. Only four studies reported one or more side effects, while six did not report side effects at all. The authors specifically highlighted the lack of standardized safety reporting as a major weakness in the evidence. Not reporting an adverse effect is different from demonstrating that an adverse effect did not occur.

What about serious psychiatric reactions?

Serious psychiatric reactions appear uncommon in the published microdosing literature, but certain people may face substantially greater risk from psychedelics. The 2026 review identified one study reporting severe anxiety and other serious psychiatric symptoms, although some of the more severe symptoms occurred at higher doses. That distinction is important because observational microdosing studies do not always use consistent dose definitions. Psilocybin can alter perception, mood and cognition, and clinical psychedelic trials commonly exclude people with certain psychiatric conditions because of concerns about mania or psychosis.

The National Center for Complementary and Integrative Health warns that psilocybin is not considered safe for people with psychotic disorders and identifies several psychiatric effects as potential risks. Microdosing should therefore not be treated as a universally low-risk version of psychedelic use simply because the amount consumed is smaller.

Side effects may become more noticeable as the dose increases

One of the clearest patterns across the literature is that unwanted effects tend to become more likely or more noticeable as psychedelic exposure increases. That creates a practical research problem: there is no universally standardized mushroom microdose. Mushroom material can also vary in potency. Two amounts that look identical by weight do not necessarily contain identical amounts of psilocybin or psilocin. A dose described by one participant as a microdose may therefore produce clearly noticeable effects in another person.

This issue also complicates research comparing one microdosing study with another.

Are side effects different on dosing days and non-dosing days?

The evidence suggests many negative effects occur acutely, meaning relatively close to when the substance is consumed. In the large survey of 1,116 current or former microdosers, negative psychological effects were most often described during the active period rather than only appearing later. Controlled psilocybin research has similarly found stronger subjective effects on dosing days without clear evidence that those same acute effects continue on non-dosing days. That does not rule out delayed or cumulative effects. Long-duration studies are still too limited to answer that question confidently.

What about heart-related side effects?

Psilocybin and other serotonergic psychedelics can temporarily affect cardiovascular measures such as blood pressure and heart rate. There is also an unresolved theoretical concern about repeated stimulation of the serotonin 5-HT2B receptor and whether chronic psychedelic exposure could have implications for heart valves. That question deserves separate treatment because acute cardiovascular effects and hypothetical long-term valvular risk are not the same thing. We cover that research in detail in our MycoNews guide, Does Psilocybin Microdosing Affect Your Heart? Blood Pressure, 5-HT2B and Heart Valve Risk.

What about medication interactions?

Medication use adds another layer of uncertainty. SSRIs, SNRIs and other medications that affect serotonin may alter the psychedelic response, while some combinations raise additional safety questions. Clinical data specifically studying repeated psilocybin microdoses alongside common psychiatric medications remain limited. For a deeper look at that evidence, see our MycoNews article Can You Microdose Psilocybin While Taking Antidepressants? SSRIs, SNRIs, Interactions and What Research Shows.

Could side effects appear only after long-term microdosing?

Researchers do not yet know. This is one of the most important unanswered questions in the field. Short-term studies can identify problems such as anxiety, headache, nausea or temporary cognitive changes. They are far less capable of detecting effects that might emerge only after months or years of repeated exposure. That is why a person experiencing few immediate side effects should not be assumed to have evidence of long-term safety.

Our article Long-Term Effects of Psilocybin Microdosing: What We Know examines that research gap in greater detail.

Does tolerance change the side-effect picture?

Classic serotonergic psychedelics can produce tolerance when exposure occurs repeatedly. Tolerance could theoretically change both desired and unwanted effects, but research has not adequately established how different microdosing schedules affect either outcome over extended periods. It also creates a problem for interpreting personal experience. Feeling fewer noticeable effects over time does not automatically mean the biological effects of repeated exposure have disappeared.

For more on that question, see Does Psilocybin Microdosing Build Tolerance?

So, is psilocybin microdosing safe?

Current evidence does not support a simple yes or no answer. Short-term studies generally suggest that adverse effects reported at low doses are more often mild and temporary than severe. Anxiety, headache, gastrointestinal discomfort, sleep problems and cognitive changes are among the effects that have been documented. At the same time:

• Microdosing doses are not standardized.
• Mushroom potency varies.
• Placebo-controlled research remains limited.
• Many studies do not adequately report adverse events.
• Long-term safety data remain sparse.
• Medication interactions are incompletely understood.
• Certain psychiatric conditions may substantially increase risk.
• Potential cardiovascular effects remain under investigation.

The strongest conclusion supported by the research is therefore not that microdosing is safe or dangerous. It is that its safety profile is still being defined.

Frequently asked questions

What are the side effects of psilocybin microdosing?

Reported side effects include anxiety, headache, nausea or stomach discomfort, appetite changes, insomnia, fatigue, restlessness, impaired concentration and temporary cardiovascular changes. Most documented effects have been mild and short-lived, but long-term safety remains uncertain.

Can microdosing make anxiety worse?

Yes. Increased anxiety has been reported in both observational research and systematic reviews of psychedelic microdosing. Responses vary considerably between individuals.

Can microdosing cause headaches?

Yes. Headaches and migraines have appeared among reported physical side effects, although researchers do not yet know how frequently psilocybin microdosing causes them.

Can microdosing make you nauseous?

Nausea and other gastrointestinal symptoms have been reported in psilocybin microdosing studies. Reduced appetite and stomach discomfort have also been described.

Can microdosing cause insomnia?

Sleep disturbance and insomnia have been reported. Research has not established that microdosing produces one consistent effect on sleep for everyone.

Does microdosing always improve focus?

No. Controlled research has not demonstrated a reliable improvement in concentration or cognitive performance. Some studies and observational reports have instead identified impaired focus or small cognitive deficits.

Are there long-term side effects of microdosing?

Long-term effects remain poorly understood because most controlled microdosing studies have been relatively short. The absence of immediate side effects does not establish long-term safety.

The bottom line

Psilocybin microdosing is not necessarily side-effect free simply because the dose is intended to be small. Current research has documented anxiety, headaches, gastrointestinal symptoms, sleep disruption, fatigue, restlessness and problems with concentration, among other unwanted effects. Most reported effects have been mild and temporary, but the evidence base has major limitations. Perhaps the most important finding from recent research is how much safety information is still missing.

The newest psilocybin-specific systematic review found that more than half of the included studies did not report side effects at all. Until longer, better-controlled studies consistently track adverse events, claims that repeated microdosing is either harmless or clearly dangerous go beyond what the evidence can currently establish. MycoNews will continue following the research as psychedelic microdosing moves from anecdote toward better-controlled clinical evidence.

Sources

Page JP, Moore A, Hawkins BE, et al. The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing. Frontiers in Psychiatry. 2026. DOI: 10.3389/fpsyt.2026.1866881. Modzelewski S, Stankiewicz A, Waszkiewicz N, Łukasiewicz K. Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes. Neuropharmacology. 2025;271:110402. DOI: 10.1016/j.neuropharm.2025.110402. Cavanna F, Muller S, de la Fuente LA, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Translational Psychiatry. 2022;12:307. DOI: 10.1038/s41398-022-02039-0.

Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC. Motives and side-effects of microdosing with psychedelics among users. International Journal of Neuropsychopharmacology. 2019;22(7):426–434. National Center for Complementary and Integrative Health. Psilocybin for Mental Health and Addiction: What You Need To Know.